Aldeyra: A Speculative Buy Amid Reproxalap’s NDA Resubmission

11 mins read
11 views

Thesis

Based on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)’s imminent catalysts (Reproxalap), considering the company holds $133 million in cash, cash equivalents and marketable securities, as per March 31st, with a market cap around $230 million, I believe ALDX is still trading at a discount. Hence, in

Read the full article here

Leave a Reply

Your email address will not be published.

Previous Story

Harris blasts Rep. Byron Donalds for comments on Black families under Jim Crow

Next Story

Activist investor takes $1.9 billion stake in Southwest Airlines, calls for leadership changes

Latest from News